BCAT-IN-2
Based on 6 publication(s) in Google Scholar
BCAT-IN-2 is a potent, selective and orally active inhibitor of mitochondrial branched-chain aminotransferase (BCATm), with a pIC50 of 7.3. BCAT-IN-2 shows selectivity for BCATm over BCATc (pIC50=6.6). BCAT-IN-2 can be used for the research of obesity and dislipidema.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.07%
- No. CAS: 1800024-45-6
- Fòrmula: C17H14ClF2N5O
- Peso molecular:377.78
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) BCAT-IN-2
More- Cell Metab. 2026 May 5;38(5):944-962.e14. [Abstract]
- Sci Adv. 2025 Jun 6;11(23):eadt3552. [Abstract]
- Cell Death Dis. 2025 Apr 24;16(1):337. [Abstract]
- Br J Cancer. 2026 May 5. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2023 Nov 4;1870(2):166941. [Abstract]
- Sci Total Environ. 2024 Jul 15:934:173254. [Abstract]
Customer Validation & Images
-
WB
-
Cell Migration/Invasion Assay
-
Cell Migration/Invasion Assay
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
Actividad biológica
pIC50: 7.3 (BCATm), 6.6 (BCATc)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDA-MB-231 | IC50 |
564 μM
Compound: Cpd A
|
Upregulation of BCAA expression in human MDA-MB-231 cells
Upregulation of BCAA expression in human MDA-MB-231 cells
|
[PMID: 36261130] |
| U-87MG ATCC | IC50 |
5.3 μM
Compound: Cpd A
|
Upregulation of BCAA expression in human U-87 MG cells
Upregulation of BCAA expression in human U-87 MG cells
|
[PMID: 36261130] |
BCAT-IN-2 (compound 61) inhibits BCATm in differentiated primary human adipocyte, with pIC50 of 6.5[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
BCAT-IN-2 (5 mg/kg for p.o. and 1 mg/kg for i.v.) exhibits a high bioavailability (F=100%), long half-life (t1/2=9.2 h) and low clearance (Cl=0.3 mL/min/kg) in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 1800024-45-6
-
Appearance Solid
-
Peso molecular 377.78
-
Fòrmula C17H14ClF2N5O
-
Color White to yellow
-
SMILES
N#CC1=C2NC(CCC)=CC(N2N=C1NCC3=C(F)C=C(Cl)C=C3F)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
2026 May 5;38(5):944-962.e14. PMID: 41720105 -
Sci Adv
HDAC7 promotes renal cancer progression by reprogramming branched-chain amino acid metabolism. [Abstract]2025 Jun 6;11(23):eadt3552. PMID: 40465706 -
Cell Death Dis
BCAT2 binding to PCBP1 regulates the PI3K/AKT signaling pathway to inhibit autophagy-related apoptosis and ferroptosis in prostate cancer. [Abstract]2025 Apr 24;16(1):337. PMID: 40274762
BCAT-IN-2 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 24;16(1):337. [Abstract]
BCAT-IN-2 (0, 25, 50 μM; 48 h) increased the expression of SANIL1 in WT and HDAC7 KO 769-P cells.
BCAT-IN-2 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 24;16(1):337. [Abstract]
BCAT-IN-2 inhibited cell migration in HDAC7 KO 769-P cells.
BCAT-IN-2 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 24;16(1):337. [Abstract]
BCAT-IN-2 (25, 50 μM; 16 h) rescued invasive behaviors in HDAC7 KO cells.
-
Br J Cancer
Blocking mitochondrial leucine transamination enhances T-cell activation and improves T-cell immunity against OVA-producing EL4 lymphoma. [Abstract]2026 May 5. PMID: 42086670 -
Biochim Biophys Acta Mol Basis Dis
Deficiency of BCAT2-mediated branched-chain amino acid catabolism promotes colorectal cancer development. [Abstract]2023 Nov 4;1870(2):166941. PMID: 37926361
BCAT-IN-2 purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta Mol Basis Dis. 2023 Nov 4;1870(2):166941. [Abstract]
BCAT-IN-2 (20 mg/kg; PO; daily) decreased tumor volume in wild-type HCT116-xenograft mouse models.
BCAT-IN-2 purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta Mol Basis Dis. 2023 Nov 4;1870(2):166941. [Abstract]
BCAT-IN-2 (20 mg/kg; PO; daily) decreased the percentage of Ki-67-positive cells in wild-type HCT116-xenograft mouse models compared with BCAT2-overexpressing (BCAT2) and BCAT2-knockdown (BCAT2-KD) groups.
-
Sci Total Environ
Interior decorative volatile organic compounds exposure induces sleep disorders through aberrant branched chain amino acid transaminase 2 mediated glutamatergic signaling resulting from a neuroinflammatory cascade. [Abstract]2024 Jul 15:934:173254. PMID: 38761924
BCAT-IN-2 purchased from MedChemExpress. Usage Cited in: Sci Total Environ. 2024 Jul 15:934:173254. [Abstract]
BCAT-IN-2 (0, 25, 50, 100, 200 μM) inhibited cell viability in C8-D1A cells.
Solvente y solubilidad
DMSO : 50 mg/mL (132.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (273 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6470 mL | 13.2352 mL | 26.4704 mL | 66.1761 mL |
| 5 mM | 0.5294 mL | 2.6470 mL | 5.2941 mL | 13.2352 mL | |
| 10 mM | 0.2647 mL | 1.3235 mL | 2.6470 mL | 6.6176 mL | |
| 15 mM | 0.1765 mL | 0.8823 mL | 1.7647 mL | 4.4117 mL | |
| 20 mM | 0.1324 mL | 0.6618 mL | 1.3235 mL | 3.3088 mL | |
| 25 mM | 0.1059 mL | 0.5294 mL | 1.0588 mL | 2.6470 mL | |
| 30 mM | 0.0882 mL | 0.4412 mL | 0.8823 mL | 2.2059 mL | |
| 40 mM | 0.0662 mL | 0.3309 mL | 0.6618 mL | 1.6544 mL | |
| 50 mM | 0.0529 mL | 0.2647 mL | 0.5294 mL | 1.3235 mL | |
| 60 mM | 0.0441 mL | 0.2206 mL | 0.4412 mL | 1.1029 mL | |
| 80 mM | 0.0331 mL | 0.1654 mL | 0.3309 mL | 0.8272 mL | |
| 100 mM | 0.0265 mL | 0.1324 mL | 0.2647 mL | 0.6618 mL |
BCAT-IN-2 Related Classifications
HY-141669 Related Classifications
Powered by Bioz